8-K: NovaBay Regains NYSE American Listing Compliance

NovaBay Pharmaceuticals, Inc. announced it has regained compliance with the NYSE American's continued listing standards by increasing its stockholders' equity above the $6 million minimum.

Summary

• NovaBay Pharmaceuticals, Inc. has regained compliance with the NYSE American's continued listing standards, as confirmed by a letter from NYSE American dated October 20, 2025.
• The company was previously notified on April 18, 2024, and May 28, 2024, of non-compliance with Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide, which require a minimum stockholders' equity of $6.0 million.
• To resolve the deficiency, NovaBay issued and sold pre-funded warrants for 5,405,406 shares of common stock, generating approximately $6.0 million in net proceeds.
• Additionally, the company issued and sold 268,750 shares of Series E non-voting convertible preferred stock, yielding approximately $2.15 million in net proceeds.
• These actions resulted in the company believing it currently has stockholders' equity in excess of the $6 million minimum requirement.
• The NYSE American had accepted the company's plan to regain compliance on June 4, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company successfully resolved a critical regulatory compliance issue that could have led to delisting. This removes a significant overhang and stabilizes its market position, though it doesn't directly reflect operational growth or profitability.

Positives

• Successfully regained compliance with NYSE American continued listing standards, removing the threat of delisting.
• Successfully executed a capital raise, securing approximately $6.0 million from pre-funded warrants and $2.15 million from preferred stock, totaling $8.15 million in net proceeds.
• Resolved all deficiencies related to Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.

Negatives

• Previously faced non-compliance with NYSE American listing standards due to insufficient stockholders' equity.
• Required a significant capital raise to meet basic listing requirements, indicating prior financial challenges.

Risks

• Ability to remain a publicly listed company by complying with all NYSE American listing standards, including maintaining the minimum stockholder equity in the future.
• General business risks detailed in NovaBay's latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading Risk Factors.

Future Outlook

The company's future outlook includes maintaining its NYSE American listing status and complying with all listing standards, including the minimum stockholder equity requirement. Management also anticipates future momentum and generally expects positive future financial results, though these are subject to known and unknown risks and uncertainties.

Management Comments

• NovaBay Pharmaceuticals, Inc. has regained compliance with the NYSE American's continued listing standards.

Industry Context

For small-cap pharmaceutical and biotechnology companies, maintaining compliance with exchange listing standards is crucial for market access and investor confidence. Non-compliance, particularly regarding minimum equity requirements, can signal financial distress and lead to delisting, severely impacting a company's ability to raise capital and trade publicly. NovaBay's successful resolution of its compliance issue is a positive step, aligning it with the basic operational expectations of publicly traded entities in the sector.

Comparison to Industry Standards

• Meeting minimum listing standards, such as the $6 million stockholders' equity requirement, is a fundamental expectation for all publicly traded companies on major exchanges like NYSE American.
• While NovaBay's regaining of compliance is a positive step, it primarily addresses a deficiency rather than demonstrating superior financial performance compared to industry peers who consistently maintain these standards.
• The capital raise was specifically to meet this minimum, not necessarily for growth initiatives that would typically be compared against competitors' strategic investments.

Stakeholder Impact

• Shareholders: Positive impact by removing the risk of delisting, which preserves liquidity and market access for their investment.
• Investors (new and existing): The successful capital raise demonstrates investor confidence and provides necessary funds to meet regulatory requirements.
• Employees: Stability in the company's public listing status can contribute to job security and morale.

Next Steps

• Continue to comply with all NYSE American listing standards, including maintaining the minimum stockholder equity in the future.

Key Dates

Recommendation

The company's regaining of NYSE American compliance is a crucial positive development, removing a significant delisting risk and stabilizing its market presence. However, this action primarily addresses a past deficiency rather than signaling strong operational growth or profitability. While the capital raise improved the balance sheet to meet minimum requirements, it doesn't inherently suggest a robust growth trajectory. Therefore, a 'hold' recommendation is appropriate, acknowledging the removal of a major negative catalyst while awaiting further evidence of sustainable operational improvement and strategic growth initiatives.

Keywords

NovaBay Pharmaceuticals, NBY, NYSE American, Listing Compliance, Stockholders Equity, Capital Raise, Pre-funded Warrants, Preferred Stock, Regulatory Compliance, Delisting Threat